文献速递鼻科

内镜下翼管及翼管分支神经切断术治疗难治性变应性鼻炎的系统评价

Endoscopic vidian and vidian-branch neurectomy for refractory allergic rhinitis: A systematic review.
PubMed 文献 · Int Forum Allergy Rhinol · 2023-09-16

该系统评价纳入24项临床研究、1677例难治性变应性鼻炎患者,评估内镜下翼管神经切断术(EVN)及翼管分支神经切断术(含SVN和PNN)的疗效。术后患者报告结局指标(RQLQ和VAS)较术前显著改善,翼管分支神经切断术并发症极少,而EVN更易引起眼干和腭部麻木。对于合并慢性鼻窦炎伴鼻息肉(CRSwNP)者,翼管或选择性翼管神经切断术联合FESS优于常规FESS。

要点

  • EVN和翼管分支神经切断术均可显著改善难治性AR患者术后RQLQ和VAS评分。
  • SVN和PNN并发症极少,EVN更易引起眼干和腭部麻木,无其他严重并发症。
  • 合并CRSwNP者,翼管或选择性翼管神经切断术联合FESS优于常规FESS。

核心结论

  • EVN和翼管分支神经切断术(包括SVN和PNN)是有效的治疗手段,但前者并发症风险更高。
  • 翼管分支神经切断术联合FESS对混合性CRSwNP患者有益。
  • SVN是合并哮喘的AR患者的一种潜在治疗选择。

研究设计与样本

  • 遵循PRISMA指南的系统评价与Meta分析,纳入报告EVN和翼管分支神经切断术(含SVN和PNN)原始患者数据的原始研究。
  • 共纳入24项临床研究、1677例难治性AR患者,其中6项研究510例合并CRSwNP,1项研究95例合并哮喘。
  • 主要结局为患者报告结局指标(PROMs),包括鼻结膜炎生活质量问卷(RQLQ)和视觉模拟量表(VAS)。
  • 次要结局为手术并发症发生率及其他客观结局。

主要发现

  • 几乎所有接受翼管神经切断术的患者术后PROMs显著优于术前(RQLQ:SMD=2.66,95%CI=2.40-2.92,p<0.001;VAS:SMD=5.15,95%CI=4.29-6.02,p<0.001)。
  • PNN术后PROMs显著优于术前(RQLQ:SMD=3.29,95%CI=2.45-4.13,p<0.001;VAS:SMD=4.38,95%CI=3.41-5.34,p<0.001),且总体优于保守治疗组。
  • 以18个月为界进行随访期亚组分析,长期和短期术后患者症状均较术前显著减轻。
  • SVN和PNN并发症极少;EVN更易引起眼干和腭部麻木,无其他严重并发症。
  • 合并CRSwNP患者中,翼管或选择性翼管神经切断术联合FESS优于常规FESS(RQLQ:SMD=2.17,95%CI=1.66-2.69,p<0.001;VAS:SMD=6.42,95%CI=4.78-8.06,p<0.001)。

关键数值与推荐

  • 翼管神经切断术术后RQLQ改善SMD=2.66(95%CI=2.40-2.92,p<0.001),VAS改善SMD=5.15(95%CI=4.29-6.02,p<0.001)。
  • PNN术后RQLQ改善SMD=3.29(95%CI=2.45-4.13,p<0.001),VAS改善SMD=4.38(95%CI=3.41-5.34,p<0.001)。
  • 合并CRSwNP者联合FESS对比常规FESS:RQLQ的SMD=2.17(95%CI=1.66-2.69,p<0.001),VAS的SMD=6.42(95%CI=4.78-8.06,p<0.001)。
  • SVN和PNN并发症极少,EVN更易引起眼干和腭部麻木。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic vidian neurectomy is expected to provide good therapeutic relief in patients with allergic rhinitis (AR) being refractory to medication therapy or conservative surgery. However, the evidence bases for its benefit remain debatable. In this study, we conducted a systematic review and meta-analysis to clarify the therapeutic role of various forms of vidian neurectomy in refractory AR. METHOD: Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were used to conduct a systematic review of primary studies that reported original patient data for endoscopic vidian neurectomy (EVN) and vidian-branch neurectomy, which includes selective vidian neurectomy (SVN) and posterior nasal neurectomy (PNN). The primary outcome was patient-reported outcome measures (PROMs), including the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and Visual Analog Scale (VAS), to assess an improvement in nasal symptom severity and quality of patient's life. The incidence of surgical complications and other objective outcomes were considered secondary outcomes. RESULTS: This review included 24 clinical studies involving 1677 patients with refractory AR, of which 510 patients in six studies had combined chronic rhinosinusitis with nasal polyps (CRSwNP) and 95 patients in one study had combined asthma. Postoperative PROMs were significantly better than preoperatively in almost all patients who underwent vidianp (RQLQ: standardized mean difference [SMD] = 2.66, 95% confidence interval [CI] = 2.40-2.92, p < 0.001; VAS: SMD = 5.15, 95% CI = 4.29-6.02, p < 0.001) or vidian-branch neurectomy (RQLQ in PNN: SMD = 3.29, 95% CI = 2.45-4.13, p < 0.001; VAS in PNN: SMD = 4.38, 95% CI = 3.41-5.34, p < 0.001), and were generally better than in the conservative treatment group. Dividing with 18 months as the cutoff point, a subgroup analysis of the follow-up period was conducted, and the results showed that both long-term and short-term postoperative patients had considerably reduced symptoms compared to the preoperative period. The two surgical procedures, SVN and PNN, attributed to vidian-branch neurectomy have extremely few complications. However, EVN is more likely to cause dry eyes and palatal numbness, with no other serious complications. In patients with AR and CRSwNP, vidian or selective vidian neurectomy combined with functional endoscopic sinus surgery (FESS) is more effective than conventional FESS (RQLQ: SMD = 2.17, 95% CI = 1.66-2.69, p < 0.001; VAS: SMD = 6.42, 95% CI = 4.78-8.06, p < 0.001). For patients who have both AR and asthma, SVN with pharyngeal branch excision is a potential treatment option. CONCLUSION: EVN and vidian-branch neurectomy (including SVN and PNN) are effective treatments, but the former has a higher risk of complications. Additionally, vidian-branch neurectomy with FESS is beneficial for patients with mixed CRSwNP. SVN is a potential approach for patients with coexisting AR and asthma.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Niu X, Chen Y, Zhou T, et al. Endoscopic vidian and vidian-branch neurectomy for refractory allergic rhinitis: A systematic review. Int Forum Allergy Rhinol. 2023. PMID: 37715589. doi:10.1002/alr.23259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。